From Allergy Med to Metabolic Hack | The Amlexanox Breakdown

Sep 30, 2025

In this insightful discussion, amlexanox emerges as a game-changing compound with unexpected metabolic benefits. The host shares personal trials and key mechanisms involved, including IKKε/TBK1 inhibition and FGF21 influences. Discover the encouraging mouse data supporting fat loss and cardiovascular health. The human trial results hint at significant improvements in glycemic control and inflammation reduction. Safety profiles are reassuring, offering a promising option for those struggling with stubborn fat and metabolic issues.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ANECDOTE

Discovery And First Personal Trial

Hunter Williams found amlexanox browsing a research-chem catalog and tried it experimentally on himself.
He noticed increased dryness in his abdominal area the next day and kept testing the compound later.

ANECDOTE

Revisiting Amlexanox For FGF21

Hunter stopped other compounds and later revisited amlexanox when researching FGF21 during the 2025 sugar diet experiment.
He sourced higher-dose material (100–150 mg) and reported much stronger fat-loss effects at that range.

INSIGHT

Releasing Metabolic 'Breaks' In Fat

Amlexanox inhibits IKKε and TBK1 kinases that become elevated in obesity and activate PDE3B.
This restores cAMP signaling, resensitizes adipocytes to catecholamines, and increases energy expenditure.

Get the Snipd Podcast app to discover more snips from this episode

Get the app